Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ionis Pharmaceuticals Inc (IONS) Common Stock USD0.001

Sell:$36.44 Buy:$36.46 Change: $0.53 (1.43%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$36.44
Buy:$36.46
Change: $0.53 (1.43%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$36.44
Buy:$36.46
Change: $0.53 (1.43%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Contact details

Address:
2855 Gazelle Ct
CARLSBAD
92010-6670
United States
Telephone:
+1 (760) 9319200
Website:
https://www.ionispharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IONS
ISIN:
US4622221004
Market cap:
$5.11 billion
Shares in issue:
141.15 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Loscalzo
    Chairman of the Board
  • Brett Monia
    Chief Executive Officer, Director
  • Elizabeth Hougen
    Chief Financial Officer, Executive Vice President
  • C. Frank Bennett
    Executive Vice President, Chief Scientific Officer
  • Patrick O'Neil
    Executive Vice President, Legal and General Counsel
  • Onaiza Cadoret-Manier
    Executive Vice President, Chief Corporate Development and Commercial Officer
  • Richard Geary
    Executive Vice President, Chief Development Officer
  • Eugene Schneider
    Executive Vice President, Chief Clinical development Officer
  • Eric Swayze
    Executive Vice President - Research
  • B. Lynne Parshall
    Director, Senior Strategic Advisor

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.